Nov 29, 2023 8:05am EST Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
Nov 28, 2023 8:15am EST Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
Nov 16, 2023 8:15am EST Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
Oct 18, 2023 8:15am EDT Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
Oct 11, 2023 8:15am EDT Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit
Sep 26, 2023 8:15am EDT Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study